Page 1932 - Williams Hematology ( PDFDrive )

1906 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1907

1388. Santos-Martinez MJ, et al: Matrix metalloproteinases in platelet function: Coming of 1423. Oury C, et al: Overexpression of the platelet P2X1 ion channel in transgenic mice
age. J Thromb Haemost 6(3):514–516, 2008. generates a novel prothrombotic phenotype. Blood 101(10):3969–3976, 2003.
1389. Soslau G, et al: Intracellular matrix metalloproteinase-2 (MMP-2) regulates human 1424. Greco NJ, et al: Novel structurally altered P(2X1) receptor is preferentially activated
platelet activation via hydrolysis of talin. Thromb Haemost 111(1):140–153, 2014. by adenosine diphosphate in platelets and megakaryocytic cells. Blood 98(1):100–107,
1390. Trivedi V, et al: Platelet matrix metalloprotease-1 mediates thrombogenesis by activat- 2001.
ing PAR1 at a cryptic ligand site. Cell 137(2):332–343, 2009. 1425. Raju NC, Eikelboom JW, Hirsh J, Platelet ADP-receptor antagonists for cardiovascular
1391. Choi WS, et al: MMP-2 regulates human platelet activation by interacting with integ- disease: Past, present and future. Nat Clin Pract Cardiovasc Med 5(12):766–780, 2008.
rin alphaIIbbeta3. J Thromb Haemost 6(3):517–523, 2008. 1426. Herbert JM, Savi P: P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin
1392. Gresele P, et al: Platelets release matrix metalloproteinase-2 in the coronary circu- Vasc Med 3(2):113–122, 2013.
lation of patients with acute coronary syndromes: Possible role in sustained platelet 1427. Banga HS, et al: Activation of phospholipases A and C in human platelets exposed
activation. Eur Heart J 32(3):316–325, 2011. to epinephrine: Role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl
1393. Rahman M, et al: Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 Acad Sci U S A 83(23):9197–9201, 1986.
in abdominal sepsis. J Thromb Haemost 11(7):1385–1398, 2013. 1428. Lanza F, et al: Epinephrine potentiates human platelet activation but is not an aggre-
1394. Stalker TJ, et al: Platelet signaling. Handb Exp Pharmacol (210):59–85, 2012. gating agent. Am J Physiol 255(6 Pt 2):1276–1288, 1988.
1395. Pawelczyk T: Isozymes delta of phosphoinositide-specific phospholipase C. Acta Bio- 1429. Shattil SJ, Budzynski A, Scrutton MC: Epinephrine induces platelet fibrinogen recep-
chim Pol 46(1):91–98, 1999. tor expression, fibrinogen binding, and aggregation in whole blood in the absence of
1396. Hirata T, et al: Two thromboxane A2 receptor isoforms in human platelets. Opposite other excitatory agonists. Blood 73(1):150–158, 1989.
coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin 1430. Kobilka BK, et al: Cloning, sequencing, and expression of the gene coding for the
Invest 97(4):949–956, 1996. human platelet alpha 2-adrenergic receptor. Science 238(4827):650–656, 1987.
1397. Murphy CT, Westwick J: Selective inhibition of protein kinase C. Effect on platelet-ac- 1431. Regan JW, et al: Purification and characterization of the human platelet alpha 2-
tivating- factor-induced platelet functional responses. Biochem J 283(Pt 1):159–164, adrenergic receptor. J Biol Chem 261(8):3894–3900, 1986.
1992. 1432. Yang J, et al: Loss of signaling through the G protein, Gz, results in abnormal plate-
1398. Cattaneo M: The platelet P2 receptors, in Platelets, edited by AD Michelson, 201–220. let activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A
Academic Press, San Diego, 2007. 97(18):9984–9989, 2000.
1399. Kunapuli SP: Funcional characterization of platelet ADP. Platelets 9:343–351, 1998. 1433. Haslam RJ, et al: Cyclic nucleotides in platelet function. Thromb Haemost 40(2):
1400. Murugappa S, Kunapuli SP: The role of ADP receptors in platelet function. Front 232–240, 1978.
Biosci 11:1977–1986, 2006. 1434. Homcy CJ, Graham RM: Molecular characterization of adrenergic receptors. Circ Res
1401. Moheimani F, Jackson DE: P2Y12 receptor: Platelet thrombus formation and medical 56(5):635–650, 1985.
interventions. Int J Hematol 96(5):572–587, 2012. 1435. Salzman EW, Ware JA: Ionized calcium as an intracellular messenger in blood plate-
1402. Conley PB, Delaney SM: Scientific and therapeutic insights into the role of the platelet lets. Prog Hemost Thromb 9:177–202, 1989.
P2Y12 receptor in thrombosis. Curr Opin Hematol 10(5):333–338, 2003. 1436. Yang J, et al: Signaling through Gi family members in platelets. Redundancy and
1403. Dorsam RT, Kunapuli SP: Central role of the P2Y12 receptor in platelet activation. J specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem
Clin Invest 113(3):340–345, 2004. 277(48):46035–46042, 2002.
1404. Hollopeter G, et al: Identification of the platelet ADP receptor targeted by antithrom- 1437. Patel YM, et al: Evidence for a role for Galphai1 in mediating weak agonist-induced
botic drugs. Nature 409(6817):202–207, 2001. platelet aggregation in human platelets: Reduced Galphai1 expression and defec-
1405. Jin J, Daniel JL, Kunapuli SP: Molecular basis for ADP-induced platelet activation. tive Gi signaling in the platelets of a patient with a chronic bleeding disorder. Blood
II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and 101(12):4828–4835, 2003.
shape change in platelets. J Biol Chem 273(4):2030–2034, 1998. 1438. Freeman K, et al: Genetic polymorphism of the alpha 2-adrenergic receptor is associ-
1406. Mills DC, et al: Clopidogrel inhibits the binding of ADP analogues to the receptor ated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in
mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 12(4):430–436, normotensive humans. Am J Hypertens 8(9):863–869, 1995.
1992. 1439. Small KM, et al: An asn to lys polymorphism in the third intracellular loop of the
1407. Cunningham MR, Nisar SP, Mundell SJ: Molecular mechanisms of platelet P2Y(12) human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi cou-
receptor regulation. Biochem Soc Trans 41(1):225–230, 2013. pling. J Biol Chem 275(49):38518–38523, 2000.
1408. Andre P, et al: P2Y12 regulates platelet adhesion/activation, thrombus growth, and 1440. von KR, Dimsdale JE: Effects of sympathetic activation by adrenergic infusions on
thrombus stability in injured arteries. J Clin Invest 112(3):398–406, 2003. hemostasis in vivo. Eur J Haematol 65(6):357–369, 2000.
1409. Foster CJ, et al: Molecular identification and characterization of the platelet ADP 1441. Bertha BG, Folts JD: Inhibition of epinephrine-exacerbated coronary thrombus for-
receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107(12): mation by prostacyclin in the dog. J Lab Clin Med 103:204–214, 1984.
1591–1598, 2001. 1442. Folts JD, Rowe GG: Epinephrine potentiation of in vivo stimuli reverses aspirin inhibi-
1410. Fontana P, et al: Adenosine diphosphate-induced platelet aggregation is associated tion of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res
with P2Y12 gene sequence variations in healthy subjects. Circulation 108(8):989–995, 50:507–516, 1988.
2003. 1443. Sibbing D, et al: Platelet function in clopidogrel-treated patients with acute coronary
1411. Staritz P, et al: Platelet reactivity and clopidogrel resistance are associated with the H2 syndrome. Blood Coagul Fibrinolysis 18(4):335–339, 2007.
haplotype of the P2Y(12)-ADP receptor gene. Int J Cardiol 133(3):341–345, 2009. 1444. Marcus A: Platelet eicosanoid metabolism, in Hemostasis and Thrombosis: Basic Prin-
1412. Zhang D, Gao ZG, Zhang K: et al: Two disparate ligand-binding sites in the human ciples and Clinical Practice, edited by RW Colman, Hirsch J, Marder VJ, Salzman EW,
P2Y1 receptor. Nature 520(7547):317–321, 2015. pp 676–688. JB Lippincott, Philadelphia, 1987.
1413. Fabre JE, et al: Decreased platelet aggregation, increased bleeding time and resistance 1445. Puri RN: Phospholipase A2: Its role in ADP- and thrombin-induced platelet activa-
to thromboembolism in P2Y1-deficient mice. Nat Med 5(10):1199–1202, 1999. tion mechanisms. Int J Biochem Cell Biol 30(10):1107–1122, 1998.
1414. Leon C, et al: Defective platelet aggregation and increased resistance to thrombosis in 1446. Wong DA, et al: Discrete role for cytosolic phospholipase A(2)alpha in platelets: Stud-
purinergic P2Y(1) receptor-null mice. J Clin Invest 104(12):1731–1737, 1999. ies using single and double mutant mice of cytosolic and group IIA secretory phos-
1415. Offermanns S, et al: Defective platelet activation in G alpha(q)-deficient mice. Nature pholipase A(2). J Exp Med 196(3):349–357, 2002.
389(6647):183–186, 1997. 1447. Adler DH, Cogan JD, Phillips JA 3rd, et al: Inherited human cPLA(2alpha)deficiency
1416. MacKenzie AB, Mahaut-Smith MP, Sage SO: Activation of receptor-operated cat- is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and
ion channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem platelet dysfunction. J Clin Invest 118(6):2121–2131, 2008.
271(6):2879–2881, 1996. 1448. Prevost N, et al: Group IVA cytosolic phospholipase A2 (cPLA2alpha) and integrin
1417. Valera S, et al: A new class of ligand-gated ion channel defined by P2x receptor for alphaIIbbeta3 reinforce each other’s functions during alphaIIbbeta3 signaling in
extracellular ATP. Nature 371(6497):516–519, 1994. platelets. Blood 113(2):447–457, 2009.
1418. Oury C, et al: Does the P(2X1del) variant lacking 17 amino acids in its extracel- 1449. Crofford LJ: COX-1 and COX-2 tissue expression: Implications and predictions. J
lular domain represent a relevant functional ion channel in platelets? Blood 99(6): Rheumatol 24(Suppl 49):15–19, 1997.
2275–2277, 2002. 1450. Warner TD, Mitchell JA: Cyclooxygenases: New forms, new inhibitors, and lessons
1419. Vial C, et al: Lack of evidence for functional ADP-activated human P2X1 receptors from the clinic. FASEB J 18(7):790–804, 2004.
supports a role for ATP during hemostasis and thrombosis. Blood 102(10):3646–3651, 1451. Dubois RN, et al: Cyclooxygenase in biology and disease. FASEB J 12(12):1063–1073,
2003. 1998.
1420. Oury C, et al: P2X(1)-mediated activation of extracellular signal-regulated kinase 1452. Smith JB, Willis AL: Aspirin selectively inhibits prostaglandin production in human
2 contributes to platelet secretion and aggregation induced by collagen. Blood platelets. Nat New Biol 231(25):235–237, 1971.
100(7):2499–2505, 2002. 1453. Svensson J, Hamberg M, Samuelsson B: On the formation and effects of thromboxane
1421. Vial C, et al: A study of P2X1 receptor function in murine megakaryocytes and human A2 in human platelets. Acta Physiol Scand 98(3):285–294, 1976.
platelets reveals synergy with P2Y receptors. Br J Pharmacol 135(2):363–372, 2002. 1454. Rocca B, et al: Cyclooxygenase-2 expression is induced during human megakary-
1422. Hechler B, et al: A role of the fast ATP-gated P2X1 cation channel in thrombosis of opoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A
small arteries in vivo. J Exp Med 198(4):661–667, 2003. 99(11):7634–7639, 2002.

Kaushansky_chapter 112_p1829-1914.indd 1907 17/09/15 3:30 pm